Patents by Inventor Elizabeth Somers

Elizabeth Somers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF HE4 AND OTHER BIOCHEMICAL MARKERS FOR ASSESSMENT OF OVARIAN CANCERS
    Publication number: 20240133889
    Abstract: The disclosure relates to use of the HE4/HE4a marker(s) together with one or more other markers to assess ovarian cancers in a patient.
    Type: Application
    Filed: October 25, 2023
    Publication date: April 25, 2024
    Inventors: Richard Moore, Elizabeth Somers
  • Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers
    Publication number: 20200292549
    Abstract: The disclosure relates to use of the HE4/HE4a marker(s) to assess endometrial and uterine cancer in a patient. The disclosure also relates to using tumors marks for diagnosis, grading and staging of endometrial and uterine cancers. The disclosure also relates to determining prognosis and treatment effectiveness of a patient who has been diagnosed with endometrial or uterine cancer.
    Type: Application
    Filed: February 4, 2020
    Publication date: September 17, 2020
    Applicant: FUJIREBIO DIAGNOSTICS, INC.
    Inventors: Richard MOORE, Elizabeth SOMERS, W. Jeffrey ALLARD
  • USE OF HE4 AND OTHER BIOCHEMICAL MARKERS FOR ASSESSMENT OF OVARIAN CANCERS
    Publication number: 20200182878
    Abstract: The disclosure relates to use of the HE4/HE4a marker(s) together with one or more other markers to assess ovarian cancers in a patient.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 11, 2020
    Applicant: FUJIREBIO DIAGNOSTICS, INC.
    Inventors: Richard MOORE, Elizabeth SOMERS
  • Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers
    Publication number: 20180180620
    Abstract: The disclosure relates to use of the HE4/HE4a marker(s) to assess endometrial and uterine cancer in a patient. The disclosure also relates to using tumors marks for diagnosis, grading and staging of endometrial and uterine cancers. The disclosure also relates to determining prognosis and treatment effectiveness of a patient who has been diagnosed with endometrial or uterine cancer.
    Type: Application
    Filed: February 14, 2018
    Publication date: June 28, 2018
    Applicant: FUJIREBIO AMERICA, INC.
    Inventors: Richard MOORE, Elizabeth SOMERS, W. Jeffrey ALLARD
  • USE OF HE4 AND OTHER BIOCHEMICAL MARKERS FOR ASSESSMENT OF OVARIAN CANCERS
    Publication number: 20180156805
    Abstract: The disclosure relates to use of the HE4/HE4a marker(s) together with one or more other markers to assess ovarian cancers in a patient.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 7, 2018
    Applicant: Fujirebio America, Inc.
    Inventors: Richard Moore, Elizabeth Somers
  • Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers
    Publication number: 20080020473
    Abstract: The disclosure relates to use of the HE4/HE4a marker(s) to assess endometrial and uterine cancer in a patient. The disclosure also relates to using tumors marks for diagnosis, grading and staging of endometrial and uterine cancers. The disclosure also relates to determining prognosis and treatment effectiveness of a patient who has been diagnosed with endometrial or uterine cancer.
    Type: Application
    Filed: January 4, 2007
    Publication date: January 24, 2008
    Inventors: Richard Moore, Elizabeth Somers, W. Allard
  • Use of HE4 and other biochemical markers for assessment of ovarian cancers
    Publication number: 20070286865
    Abstract: The disclosure relates to use of the HE4/HE4a marker(s) together with one or more other markers to assess ovarian cancers in a patient.
    Type: Application
    Filed: January 4, 2007
    Publication date: December 13, 2007
    Inventors: Richard Moore, Elizabeth Somers
  • Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity
    Publication number: 20060014211
    Abstract: The invention relates to methods and kits for assessing occurrence in patient mesothelial fluid of peptides having amino acid sequences related to those of mesothelin, megakaryocyte potentiating factor, and other peptides that have been associated with occurrence in the serum of mesothelioma patients. The methods and kits can be used to monitor the biochemical or pathological status of a component of the corresponding mesothelial cavity in a patient, to predict development of such a pathological status in an otherwise asymptomatic patient, or to assess the efficacy of a therapeutic method.
    Type: Application
    Filed: January 21, 2005
    Publication date: January 19, 2006
    Applicant: Fujirebio Diagnostics, Inc.
    Inventors: Daniel O'Shannessy, Niranjan Sardesai, Elizabeth Somers